Life Molecular Imaging – Website

Innovative PET imaging agents for earlier and improved diagnosis and better characterization of diseases

Search Icon

Menu Toggle Icon

Skip to content
  • Home
  • About us
    • Leadership Team
    • Partners
    • Business Development & Licensing
    • Compliance & Code of Conduct
    • Contacts
  • Molecular Imaging
    • How It Works
    • Value of Molecular Imaging
  • Research & Development
    • Neuro-Imaging
    • Onco-Imaging
    • Cardiovascular-Imaging
  • Products
  • News
    • Current News
    • Careers

Life Molecular Imaging is Proud to Support the New IDEAS Study to Further Demonstrate the Value of Amyloid PET for Diagnosing Alzheimer’s Disease in Diverse Communities

11. December 202011. December 2020lifemolecular

Click here to read more: Press release

Post navigation

← Tau-PET Tracer PI-2620 Could Set New Standards for an Improved Diagnosis of Progressive Supranuclear Palsy
Life Molecular Imaging announces an ongoing collaboration with UCB for
PI-2620, a novel tau imaging agent, for improved diagnosis of Progressive Supranuclear Palsy →
© Copyright 2018 Life Molecular Imaging
Data Protection & Cookies. Our site uses cookies.
Click here to learn more: Data protection
Imprint / Data protection
Contact
Scroll to Top